US · SCNI
Scinai Immunotherapeutics Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Jerusalem
- Website
- scinai.com
Price · as of 2024-12-31
$0.71
Market cap 1.17M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $369.00 | ||||
| 2016 | $554.00 | ||||
| 2017 | $634.00 | ||||
| 2018 | $482.00 | ||||
| 2019 | $824.00 | ||||
| 2020 | $424.00 | ||||
| 2021 | $121.00 | ||||
| 2022 | $21.48 | ||||
| 2023 | $5.24 | ||||
| 2024 | $3.47 |
AI valuation
Our deep-learning model estimates Scinai Immunotherapeutics Ltd.'s (SCNI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.71
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SCNI | Scinai Immunotherapeutics… | $0.71 | 1.17M | — | — | — | — | 0.58 | 0.28 | 4.25 | -0.42 | — | 0.28 | -88.15% | -1312.77% | 728.88% | 177.37% | -81.41% | 31.02% | 0.21 | -6.00 | 1.32 | 1.21 | -0.02 | -13571.00% | — | -3665.00% | -226.90% | -3.51 | -59.82% | 0.00% | 0.00% | 556.57% | -0.34 | -0.46 | 4.44 | -13.77 |
| ENVB | Enveric Biosciences, Inc. | $2.35 | 1.4M | — | — | — | — | -0.10 | 0.57 | — | 0.14 | -0.07 | 0.59 | 0.00% | — | — | -539.57% | 1966.05% | -259.40% | 0.00 | — | 1.84 | 1.50 | 0.24 | 13535.00% | — | -4520.00% | -844.14% | -5.19 | 1576.99% | 0.00% | 0.00% | 118.40% | 0.14 | 0.17 | — | -57.63 |
| INDP | Indaptus Therapeutics, In… | $2.06 | 3.61M | — | — | — | — | -14.39 | 54.78 | — | -13.69 | — | 54.78 | 0.00% | — | — | -187.52% | 1071.45% | -134.95% | 0.02 | — | 1.95 | 1.71 | 0.37 | -1250.00% | — | -807.00% | -5.70% | -3.63 | 859.29% | 0.00% | 0.00% | 0.00% | -13.69 | -17.07 | — | 20.29 |
| JSPR | Jasper Therapeutics, Inc. | $1.38 | 22.43M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| ONCO | Onconetix, Inc. | $0.67 | 381.85K | +297,429% | +1,069% | — | — | -0.01 | 0.07 | 0.25 | -0.16 | 0.00 | -0.04 | 41.80% | -2237.96% | -2325.21% | -2928.31% | -611.88% | -101.45% | 0.98 | -40.13 | 0.05 | 0.04 | -0.15 | 198134.00% | 421731.00% | -2282.00% | -1666.65% | -0.57 | -116.03% | 32.69% | -0.40% | 32.80% | -0.17 | -0.90 | 3.74 | -12.99 |
| PBM | Psyence Biomedical Ltd. | $2.54 | 48.31K | — | — | — | — | 121.05 | 18.22 | — | 113.47 | — | 18.22 | 0.00% | — | — | -47.61% | 1045.66% | 23.95% | 0.00 | -395.15 | 11.04 | 10.55 | -5.98 | -12268.00% | — | 2687.00% | -3.06% | -6.28 | 1068.81% | 0.00% | 0.00% | 12.94% | -31.76 | -31.07 | — | 112.16 |
| REVB | Revelation Biosciences, I… | $1.32 | 1.95M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
| SLRX | Salarius Pharmaceuticals,… | $0.84 | 4.92M | — | — | — | — | -0.18 | 0.67 | — | 0.21 | 0.00 | 0.67 | 0.00% | — | — | -164.02% | 1120.04% | -116.05% | 0.15 | — | 1.98 | 1.61 | 0.40 | 15226842.00% | — | -6477.00% | -445.68% | -2.99 | 883.90% | 0.00% | 0.00% | 0.00% | 0.21 | 0.26 | — | -43.21 |
| SLXN | Silexion Therapeutics Ltd… | $1.73 | 967.66K | — | — | — | — | -7.53 | -31.20 | — | -7.75 | — | -31.20 | 0.00% | — | — | 169.73% | 122.14% | -406.92% | -1.13 | -241.75 | 0.64 | 0.34 | -0.20 | -4027.00% | — | 8538.00% | -6.76% | -2.38 | 81.79% | 0.00% | 0.00% | 0.00% | -10.16 | -15.18 | — | -25.28 |
| SPRC | SciSparc Ltd. | $0.56 | 288.91K | +7,017% | +385% | — | +8,471% | -5.24 | 4.80 | 29.97 | -5.32 | — | 5.86 | 38.74% | -560.18% | -481.16% | -94.77% | -166.78% | -69.41% | 0.01 | -243.87 | 5.36 | 5.02 | 0.21 | -9850.00% | -5464.00% | -1330.00% | -13.04% | -3.65 | -116.57% | 0.00% | 0.00% | 0.00% | -5.08 | -7.28 | 28.43 | 5.04 |
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
- CEO
- Amir Reichman
- Employees
- 31
- Beta
- 1.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.71) − 1 = — (DCF, example).